The U.S. Justice Dept. could reportedly file charges in its generic-drug pricing probe into companies including Mylan Pharmaceuticals (NSDQ:MYL) and Teva Pharmaceuticals (NYSE:TEVA) by the end of year.
The department is examining whether the generic drug makers colluded on drug pricing, Bloomberg reported yesterday. The news source said that Mylan and Teva have disclosed subpoenas and are cooperating with authorities.
Get the full story at our sister site, Drug Delivery Business News.
The post Mylan, Teva crash as DOJ could file charges by end of year appeared first on MassDevice.